MedTrace Logo

Lactate Metabolism After an Endotoxin Challenge in Healthy Humans

NCT01647997 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2012-07-24

No results posted yet for this study

Summary

Sepsis is characterized by hyperlactatemia, the severity of which is proportionate with sepsis severity. The pathophysiological mechanisms (increased lactate production vs decreased lactate utilization; tissues involved in sepsis-induced lactate production) remain largely unknown.

In this study, the investigators will assess whole body and regional metabolism in healthy young male subjects on two occasions, once after administration of an intravenous bacterial endotoxin challenge, and once without intervention.

In one group of subjects, whole body lactate metabolism will be measured over 10 hours after the endotoxin challenge

* Energy expenditure and net substrate oxidation rates (indirect calorimetry)
* Lactate kinetics (measured by means of a continuous, exogenous sodium lactate infusion)
* Glucose kinetics (measured with 6,6 d2 glucose)
* Hemodynamic parameters and body temperature
* Blood clinical chemistry In one group of subjects, whole body lactate metabolism will be measured over 10 hours after the endotoxin challenge
* Energy expenditure and net substrate oxidation rates (indirect calorimetry)
* Lactate kinetics (measured by means of a continuous, exogenous sodium lactate infusion)
* Glucose kinetics (measured with 6,6 d2 glucose)
* Hemodynamic parameters and body temperature
* Blood clinical chemistry

In a second group of subjects, regional muscle lactate metabolism will be measured over 10 hours after the endotoxin challenge by means of muscle microdialysis

Conditions

Interventions

OTHER

bacterial endotoxin challenge

iv administration of 2ng/kg bacterial endotoxin

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Vaudois

    collaborator OTHER

  • University of Lausanne

    lead OTHER

Principal Investigators

  • René Chiolero, MD · Centre Hospitalier Universitaire Vaudois

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-04-30
Primary Completion
2004-03-31
Completion
2004-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01647997 on ClinicalTrials.gov